As Cell Therapy Approvals Speed Up, Companies Struggle with Manufacturing Demands

Wed, Oct 09, 2019 | By Jill Robinson, Inside Sales Manager

Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data, and now manufacturers are facing the substantial logistical challenges of scaling their products into the commercial stage.  Critical to these therapies are their environmental conditions, especially during transport. Many must maintain cryogenic temperatures while en route to the patient. Poorly managed therapy processes are very risky for the viability of these fragile treatments. Fabio Fachin, PhD, Head of Cell Therapy Engineering and Automation at Takedaexplains: “The aim of cell therapy manufacturing is to deliver a consistent product starting from an intrinsically variable starting material, often from a diseased patient, [and] that is a big task.” 

Cryoport is uniquely equipped to handle an important part of this “big task.” With the largest cryogenic dry shipper fleet in the industry, we’re supporting over 400 clinical trials worldwide and three commercial distributions, including Gilead’s YESCARTA™ and Kite’s KYMRIAH™. These autologous therapies have no room for error during transportwhich is why Cryoport utilizes over 250,000 transit legs of data, 24/7 condition monitoring, and our specifically designed packaging to proactively mitigate the risk of these therapy shipments.  

In addition to an exciting surge of approved therapies needing to address these logistical challenges, many are also anticipating future regulatory changes. One of these is the validation and traceability of equipment. We have heard this from our partners, and we have already been addressing this with Cryport’s Chain of Compliance™, providing the full traceability of our equipment and processes supporting each patient’s therapy. We’ve also introduced our new line of Advanced Therapy Shippers™, which are guaranteed for human clinical trial and commercial products to support new gene and cell therapies through all stages of their development.  

The cell and gene therapy industry is a fast-growing and fast-changing space. Cryoport is dedicated to delivering the reliability and consistency our clients need, so they can focus on their life-changing and life-saving therapies.

More Cryoport News

Tags: Frozen Shipping, frozen shipping solution, Cold Chain Logistics, Cold Chain, Clinical Trials Logistics, Global Cold Chain Logistics, alternative to dry ice shipping, stem cell frozen shipping, regenerative therapies, deep frozen shipping, cellular therapies, Temperature Controlled Logistics, cryogenic shipping, cold chain shipping, biologics, transportation, Chain of Compliance™